title: Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet for reinforcing qi and resolving stasis.
abstract: OBJECTIVE
  To investigate the efficacy and safety of the Fuzheng Huayu Tablet FZHYT), which is used to reinforce qi and resolve stasis in patients with posthepatitic cirrhosis (PHC).
  
  
  METHODS
  A multicenter, randomized, controlled clinical trial was conducted in 180 patients with PHC. The patients were randomly assigned using random numbers to a treatment group treated with FZHYT and a placebo group; the treatment course was 6 months for both groups. Overall response, adverse events (AEs), and the 2-year survival rate were assessed after treatment. Evaluations were made on changes in liver function, liver fibrosis, coagulation, hemodynamics, degrees of esophagogastric varices, ascites, quality of life (QOL), and scores of main symptoms.
  
  
  RESULTS
  The overall response was significantly higher in the treatment group than the placebo group (86.7% vs. 62.2%, P<0.01). Patients in both groups had significant improvements in liver function [total bilirubin (TBIL), albumin (ALB)], liver fibrosis [hyaluronic acid (HA), type IV collagen (CIV)], coagulation [prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), and thrombin time (TT)], hemodynamics portal venous flow (PVF), and splenic vein flow (SVF) after treatment. Between-group comparisons showed that compared with the placebo group patients in the treatment group achieved significantly greater improvements in TBIL, ALB, HA, C IV, PT, APTT, PVF, SVF, time to ascites resolution, 2-year survival, QOL, and symptom scores (P<0.05 or P<0.01). There were no significant AEs during the treatment.
  
  
  CONCLUSIONS
  FZHYT is effective and safe for the treatment of hepatic cirrhosis as it is associated with improved liver function, liver fibrosis, coagulation, portal hypertension state, QOL, 2-year survival rate, and fewer AEs.
authors.affiliation: Ruikang Hospital of Guangxi University of Chinese Medical, Nanning 530011, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Deng
authors.forename: Jian
authors.initials: J
authors.lastname: Liang
authors.forename: Zhen-Wei
authors.initials: ZW
authors.lastname: Liu
authors.forename: Fa-Sheng
authors.initials: FS
authors.lastname: Wu
authors.forename: Xuan
authors.initials: X
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D001201:Ascites / Q000150:complications / Q000473:pathology; D001777:Blood Coagulation / Q000187:drug effects; D004365:Drugs, Chinese Herbal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004932:Esophageal and Gastric Varices / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D019413:Qi; D011788:Quality of Life; D016019:Survival Analysis; D013607:Tablets; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D004365:Drugs, Chinese Herbal; D013607:Tablets; C532829:fuzheng huayu
references.citation: Clin Biochem. 2010 Jul;43(10-11):877-81
references.pmid: 20433821
references.citation: Liver Int. 2007 Sep;27(7):879-90
references.pmid: 17696925
references.citation: Hepatobiliary Pancreat Dis Int. 2006 May;5(2):224-7
references.pmid: 16698580
references.citation: Radiographics. 2009 May-Jun;29(3):825-37
references.pmid: 19448118
references.citation: Gut. 2010 Jul;59(7):988-1000
references.pmid: 20581246
references.citation: World J Gastroenterol. 2006 Dec 28;12(48):7798-804
references.pmid: 17203523
references.citation: J Pharmacol Exp Ther. 2010 Jul;334(1):124-36
references.pmid: 20406856
references.citation: Zhong Yao Cai. 2006 Jul;29(7):748-52
references.pmid: 17059015
references.citation: World J Gastroenterol. 2008 Oct 21;14(39):6060-4
references.pmid: 18932286
references.citation: J Hepatol. 2001 Sep;35(3):421-30
references.pmid: 11592607
references.citation: Hepatology. 2006 Dec;44(6):1511-7
references.pmid: 17133503
references.citation: Zhonghua Gan Zang Bing Za Zhi. 2007 Apr;15(4):312-3
references.pmid: 17456328
references.citation: Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Jul;28(7):642-5
references.pmid: 18822918
references.citation: Annu Rev Pharmacol Toxicol. 2005;45:605-28
references.pmid: 15471534
references.citation: Hepatology. 2007 Feb;45(2):507-39
references.pmid: 17256718
references.citation: J Huazhong Univ Sci Technolog Med Sci. 2009 Feb;29(1):53-8
references.pmid: 19224163
references.citation: J Biomed Biotechnol. 2010;2010:138237
references.pmid: 20617133
references.citation: Gut. 2011 Sep;60(9):1254-9
references.pmid: 21504996